At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 15 enrolled
Drug / intervention
Misoprostol - buccal +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immune Modulation by Misoprostol
In Brief
A Early Phase 1 clinical trial evaluating Misoprostol - buccal and Misoprostol - vaginal for Gynecological Infection. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The present study is designed to address the null hypothesis that there is no difference in the local and systemic immunomodulatory effects of buccally or vaginally administered misoprostol in healthy, reproductive-age women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGynecological Infection
CountriesUnited States
CollaboratorsGynuity Health Projects
Timeline
Early Ph 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2014
Primary CompletionJul 2015
Study CompletionNov 2015
TodayJul 2026
First PostedOct 8, 2014
Enrollment StartNov 1, 2014
Primary CompletionJul 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.7 years ago
Interventions
Misoprostol - buccaldrug
buccal administration
Misoprostol - vaginaldrug
vaginal administration